Comment: Reasons for early abacavir discontinuation in HIV-infected patients.
Parra-Ruiz
Jorge
J
Martínez-Ramírez
Mariela
M
Muñoz-Medina
Leopoldo
L
Serrano-Falcón
Cristina
C
Hernández-Quero
José
J
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects; D016312:Treatment Refusal; D015215:Zidovudine / Q000009:adverse effects; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D015215:Zidovudine; D000099227:Abacavir; C418262:abacavir, lamivudine, and zidovudine drug combination